SAN DIEGO, March 12, 2019 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that it will present a company overview and participate in 1x1 meetings at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 10:40 am ET at the Westin Grand Central Hotel in New York.
"At Forge, we are developing a pipeline of novel small molecules using our BLACKSMITH chemistry platform to tackle large-scale health issues with an initial focus on antibiotic resistance," said Zachary A. Zimmerman, Ph.D., CEO of Forge. "We look forward to presenting our story at the Needham conference and showcasing the vast number of important metalloenzyme targets, the broad therapeutic application of our technology, and our compelling preclinical data."
About Forge Therapeutics
At Forge Therapeutics, we are developing medicines targeting metal-dependent enzymes found in nature. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes. At Forge, we are the BLACKSMITHS of modern medicine, providing the tools to address any metalloenzyme challenge.
Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria, which is essential for bacteria to grow. Forge has a strategic drug discovery alliance with Evotec AG and has been awarded funding by CARB-X as well as government agencies. In addition, Forge has amassed a rich intellectual property estate on metalloenzyme-targeted inhibitors to protect its BLACKSMITH platform and pipeline including technology licensed from UCSD. For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.
Forge Company Contact:
Forge Media Contact:
SOURCE Forge Therapeutics, Inc.